Literature DB >> 25633718

A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma.

Yu-Zheng Ge1, Ran Wu, Hui Xin, Meng Zhu, Tian-Ze Lu, Hao Liu, Zheng Xu, Peng Yu, You-Cai Zhao, Ming-Hao Li, Zhi-Kai Hu, Yan Zhao, Bing Zhong, Xiao Xu, Liu-Hua Zhou, Lu-Wei Xu, Jian-Ping Wu, Wen-Cheng Li, Jia-Geng Zhu, Rui-Peng Jia.   

Abstract

PURPOSE: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancers in adults, and microRNAs (miRNAs) differentially expressed in ccRCC tumors have been identified and proposed to predict prognosis. In the present study, we comprehensively analyzed the genome-wide miRNA expression profiles in ccRCC, with the aim to generate a tumor-specific miRNA signature of prognostic values.
METHODS: The miRNA profiles in tumor and the adjacent normal tissue were analyzed, and the association of the differentially expressed miRNAs with patient survival was examined with univariate Cox regression analysis. Finally, a tumor-specific miRNA signature was generated and examined with Kaplan-Meier survival, univariate, and multivariate Cox regression analyses.
RESULTS: A total of 147 miRNAs were found differentially expressed between tumor and matched non-tumor tissues from 58 ccRCC patients. The prognostic values of these differentially expressed miRNAs were subsequently analyzed in the 411 ccRCC patients, and 22 miRNAs were found significantly correlated with patient survival. Finally, a tumor-specific miRNA signature of 22 miRNAs was generated and validated as an independent prognostic parameter.
CONCLUSIONS: A tumor-specific miRNA signature consisting of 22 miRNAs was identified and validated as an independent prognostic factor, which could serve as a novel biomarker for ccRCC prognostication and help in predicting treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25633718     DOI: 10.1007/s00432-015-1927-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  42 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

2.  Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.

Authors:  Na Liu; Nian-Yong Chen; Rui-Xue Cui; Wen-Fei Li; Yan Li; Rong-Rong Wei; Mei-Yin Zhang; Ying Sun; Bi-Jun Huang; Mo Chen; Qing-Mei He; Ning Jiang; Lei Chen; William C S Cho; Jing-Ping Yun; Jing Zeng; Li-Zhi Liu; Li Li; Ying Guo; Hui-Yun Wang; Jun Ma
Journal:  Lancet Oncol       Date:  2012-05-03       Impact factor: 41.316

3.  Active surveillance for metastatic or recurrent renal cell carcinoma.

Authors:  Inkeun Park; Jae-Lyun Lee; Jin-Hee Ahn; Dae-Ho Lee; Kyoo-Hyung Lee; In Gab Jeong; Cheryn Song; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-22       Impact factor: 4.553

4.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

Review 5.  MicroRNA and cancer.

Authors:  Martin D Jansson; Anders H Lund
Journal:  Mol Oncol       Date:  2012-10-09       Impact factor: 6.603

6.  Identification of a microRNA panel for clear-cell kidney cancer.

Authors:  David Juan; Gabriela Alexe; Travis Antes; Huiqing Liu; Anant Madabhushi; Charles Delisi; Shridhar Ganesan; Gyan Bhanot; Louis S Liou
Journal:  Urology       Date:  2009-12-29       Impact factor: 2.649

7.  Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma.

Authors:  Hiedo Hidaka; Naohiko Seki; Hirofumi Yoshino; Takeshi Yamasaki; Yasutoshi Yamada; Nijiro Nohata; Miki Fuse; Masayuki Nakagawa; Hideki Enokida
Journal:  Oncotarget       Date:  2012-01

8.  Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.

Authors:  Sakshi Gulati; Pierre Martinez; Tejal Joshi; Nicolai Juul Birkbak; Claudio R Santos; Andrew J Rowan; Lisa Pickering; Martin Gore; James Larkin; Zoltan Szallasi; Paul A Bates; Charles Swanton; Marco Gerlinger
Journal:  Eur Urol       Date:  2014-07-19       Impact factor: 20.096

9.  BRB-ArrayTools Data Archive for human cancer gene expression: a unique and efficient data sharing resource.

Authors:  Yingdong Zhao; Richard Simon
Journal:  Cancer Inform       Date:  2008-04-21

10.  Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing.

Authors:  Susanne Osanto; Yongjun Qin; Henk P Buermans; Johannes Berkers; Evelyne Lerut; Jelle J Goeman; Hendrik van Poppel
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

View more
  21 in total

1.  MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma.

Authors:  Xinwen Ke; Xing Zeng; Xian Wei; Yuanqing Shen; Jiahua Gan; Huake Tang; Zhiquan Hu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 2.  Aberrantly expressed microRNAs in bladder cancer and renal cell carcinoma.

Authors:  Akira Kurozumi; Yusuke Goto; Atsushi Okato; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-06-30       Impact factor: 3.172

3.  MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival.

Authors:  Zheng Xu; Yan-Qiu Yu; Yu-Zheng Ge; Jia-Geng Zhu; Meng Zhu; You-Cai Zhao; Lu-Wei Xu; Xiao-Bing Yang; Li-Guo Geng; Quan-Liang Dou; Rui-Peng Jia
Journal:  Tumour Biol       Date:  2015-05-20

Review 4.  MiRNAs in renal cell carcinoma.

Authors:  Jesús Miranda-Poma; Lucía Trilla-Fuertes; Elena López-Camacho; Andrea Zapater-Moros; Rocío López-Vacas; María Isabel Lumbreras-Herrera; Ana Pertejo-Fernandez; Juan Ángel Fresno-Vara; Enrique Espinosa-Arranz; Angelo Gámez-Pozo; Álvaro Pinto-Marín
Journal:  Clin Transl Oncol       Date:  2022-06-21       Impact factor: 3.340

5.  Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.

Authors:  Jesús García-Donas; Benoit Beuselinck; Lucía Inglada-Pérez; Osvaldo Graña; Patrick Schöffski; Agnieszka Wozniak; Oliver Bechter; Maria Apellániz-Ruiz; Luis Javier Leandro-García; Emilio Esteban; Daniel E Castellano; Aranzazu González Del Alba; Miguel Angel Climent; Susana Hernando; José Angel Arranz; Manuel Morente; David G Pisano; Mercedes Robledo; Cristina Rodriguez-Antona
Journal:  JCI Insight       Date:  2016-07-07

Review 6.  Background, applications and challenges of radiogenomics in genitourinary tumor.

Authors:  Longfei Liu; Xiaoping Yi; Can Lu; Yingxian Pang; Xiongbing Zu; Minfeng Chen; Xiao Guan
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

7.  A Seven-microRNA Expression Signature Predicts Survival in Hepatocellular Carcinoma.

Authors:  Jian Zhang; Charing C N Chong; George G Chen; Paul B S Lai
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

8.  Oncogenic MicroRNAs Characterization in Clear Cell Renal Cell Carcinoma.

Authors:  Vincenzo Petrozza; Antonio Carbone; Teresa Bellissimo; Natale Porta; Giovanni Palleschi; Antonio Luigi Pastore; Angelina Di Carlo; Carlo Della Rocca; Francesco Fazi
Journal:  Int J Mol Sci       Date:  2015-12-08       Impact factor: 5.923

9.  A Five-Gene Signature Predicts Prognosis in Patients with Kidney Renal Clear Cell Carcinoma.

Authors:  Yueping Zhan; Wenna Guo; Ying Zhang; Qiang Wang; Xin-jian Xu; Liucun Zhu
Journal:  Comput Math Methods Med       Date:  2015-10-11       Impact factor: 2.238

Review 10.  MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Liangyou Gu; Hongzhao Li; Luyao Chen; Xin Ma; Yu Gao; Xintao Li; Yu Zhang; Yang Fan; Xu Zhang
Journal:  Oncotarget       Date:  2015-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.